SOLV · NYSE · STOCK
Solventum (SOLV) Stock Analysis
$87.44
52W $62.38 – $94.16
63/100
$15.12B
10.6
0.70
⚠
Buy rating, but near-term risk/reward is unfavorable
The long-term recommendation is based on the composite investment score. The near-term risk/reward is based on nearby support and resistance levels. These can differ when a strong company trades close to resistance with support further below.
Is SOLV Bullish or Bearish?
Bullish.
Innellis AI committee rates Solventum (SOLV) Buy with a composite score of 63/100
, based on 5 analysts with 80% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +11.96 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -8.04 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Value Analyst sees a compelling case — p/e of 10.4 is inexpensive for the broad market. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- P/E of 10.4 is inexpensive for the broad market — Value
- ROE of 29.0% shows genuine earnings power backing the valuation — Value
- EPS growing 277.1% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- News sentiment is positive (+0.25 across 4 articles, 14d) — News
Bear Case
- Revenue declining -0.9% YoY -- this is not a growth story right now — Growth
- MACD histogram negative -- bearish momentum — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
63/100
Agreement
80%
Analysts
5
Conviction
High
Sector Rank
Top 15%
of 192 Healthcare peers
Value Analyst
bullish
70
/ 100 · Moderate confidence
Classic value case: cheap on multiples with earnings power to back it up
+ P/E of 10.4 is inexpensive for the broad market
Growth Analyst
bullish
66
/ 100 · High confidence
Strong, accelerating growth with consistent execution
+ EPS growing 277.1% YoY
− Revenue declining -0.9% YoY -- this is not a growth story right now
Technical Analyst
neutral
48
/ 100 · High confidence
Mixed or range-bound price action
− MACD histogram negative -- bearish momentum
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
66
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.25 across 4 articles, 14d)
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 62.7 to 63.0.
- Bullish support removed: 2 signal(s) disappeared.
- New bullish signals: 2 appeared.
Analyst-level changes:
- News Analyst: +1 bullish signal(s).
- Value Analyst: +1 bullish signal(s).
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
46.1
Neutral
MACD Histogram
-0.312
Bearish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Hh Hl
Support
$73.08
Resistance
$88.14
Bollinger %B
0.30
Inside Bands
Price vs Moving Averages
EMA 9
$87.44
Above
EMA 21
$88.06
Below
EMA 50
$87.05
Above
EMA 200
$80.32
Above
Fundamental Analysis
Valuation
92
Growth
95
Profitability
93
Financial Health
44
Cash Flow
15
Valuation
P/E Ratio
10.6×
P/B Ratio
3.16×
PEG Ratio
0.04
Dividend Yield
0.00%
52W High
$94.16
52W Low
$62.38
Quality & Growth
ROE
3081.8%
ROA
1088.6%
Gross Margin
5469.3%
Operating Margin
2499.4%
Revenue Growth YoY
—
Debt / Equity
1.10
AI Fundamental Assessment
P/E ratio of 10.6 (inexpensive relative to a 15-40x range); Price-to-book of 3.2x; PEG ratio of 0.0 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 30.8%; Return on assets of 10.9%; Net margin of 17.3%; Gross margin of 54.7%; Current ratio of 1.02 (tight short-term liquidity); Debt-to-equity of 1.10; Free cash flow per share is negative (-0.68); Most recent quarter beat estimates by 31.2%; 5 consecutive earnings beats; EPS growth accelerating (-5.7% -> +72.3% QoQ); Average YoY EPS growth of 50.9%; Analyst estimates rising over recent quarters
Get the Full SOLV Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →